Sera Prognostics Inc (NASDAQ:SERA) Q3 2024 Results Conference Call November 7, 2024 5:00 PM ET

Company Participants

Peter DeNardo - IR
Evguenia Lindgardt - President, CEO & Director
Austin Aerts - Chief Financial Officer

Conference Call Participants

Andrew Brackmann - William Blair

Operator

Good afternoon, and welcome to the Sera Prognostics Conference Call to review Third Quarter Fiscal Year 2024 Results. [Operator Instructions] As a reminder, the call is being recorded for replay purposes.

I would now like to turn the call over to Peter DeNardo of Capcomm Partners for a few introductory comments.

Peter DeNardo

Thank you, operator. Good afternoon, everyone. Welcome to Sera Prognostics Third Quarter Fiscal Year 2024 Earnings Conference Call. At the close of the market today, Sera Prognostics released its financial results for the quarter ended September 30, 2024. Presenting for the company today will be Evguenia Lindgardt, President and CEO; and Austin Aerts, our CFO.

During the call, we will review the financial results we released today, after which we will host a question-and-answer session. If you've not had a chance to review our quarterly earnings release, it can be found on our website at seraprognostics.com. This call can be heard live via webcast at seraprognostics.com, and a recording will be archived in the Investors section of our website.

Please note that, some of the information presented today may contain projections, or other forward-looking statements about events and circumstances that have not yet occurred, including plans and projections for our business, future financial results and market trends and opportunities. These statements are based on management's current expectations, and the actual events or results may differ materially and adversely from these expectations for a variety of reasons.

We refer you to the documents the company files from time to time with the Securities and Exchange Commission, specifically the company's annual report on Form 10-K, its quarterly reports on Form 10-Q and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in our projections and other forward-looking statements.

As a reminder, a webcast replay of this call will be available on the Investors section of our website.

I will now turn the call over to Evguenia, Sera Prognostics President and CEO. Evguenia?

Evguenia Lindgardt

Thank you so much, Peter, and good afternoon, everyone. We're solidly executing our plan for the year to support increases in test adoption and revenue. This plan, which we've communicated previously, focuses on publication of our clinical trial results, building awareness of PRETERM birth screening risks and Sera solutions, increasing payer coverage, making it easier to access our test, putting scalability in place to harness that growth.